MiNK Therapeutics Inc

NASDAQ:INKT   3:59:54 PM EDT
1.31
-0.01 (-0.76%)
Earnings Announcements

Mink Therapeutics Provides Corporate Update And Reports Fourth Quarter Results

Published: 03/18/2022 13:40 GMT
MiNK Therapeutics Inc (INKT) - Mink Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results.
Q4 Loss per Share $0.18 Including Items.
Cash Balance at December 31, 2021 is $39 Million, Reflecting Net Proceeds Received From Our Ipo During Q4.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.23

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.24

More details on our Analysts Page.